USPTO serial 97495182
VYDURA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- MATZINGER, AMY L
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with VYDURA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Andrea Christensen
Andrea Christensen Pfizer Inc.66 Hudson Boulevard EastNew York, NY 10001-2192United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, carotid endarterectomy, cardiac bypass, cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post-intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine-adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism, menopausal hot flashes; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 7, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 7, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 13, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 12, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Feb 12, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Feb 12, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 5, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 11, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 11, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 21, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 7, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 4, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 4, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 4, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 3, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 3, 2023 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| May 3, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 3, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 3, 2023 | WOAG | WITHDRAWAL OF ATTORNEY GRANTED | — |
| May 3, 2023 | WOAR | TEAS WITHDRAWAL OF ATTORNEY RECEIVED | — |
| Dec 8, 2022 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Dec 8, 2022 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 8, 2022 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 7, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 27, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 27, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 27, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 27, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 27, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 13, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 12, 2022 | NWAP | NEW APPLICATION ENTERED | — |